Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Liver Cancer-Pipeline Review, H2 2016, provides an overview of the Liver Cancer (Oncology) pipeline landscape.
Liver cancer starts in the liver. The risk factors for liver cancer include hepatitis, cirrhosis, or scarring of liver, being male and having low weight at birth. Symptoms include a lump or pain on the right side of the abdomen and yellowing of the skin. Treatment of liver cancer may include chemotherapy, radiation and surgery.
Report Highlights
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Liver Cancer-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Liver Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Liver Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Liver Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 17, 76, 52, 8, 121 and 19 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 15, 8, 1, 30 and 3 molecules, respectively.
Liver Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Cancer (Oncology).
The pipeline guide reviews pipeline therapeutics for Liver Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Liver Cancer (Oncology) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Liver Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Liver Cancer (Oncology)
Reasons to Buy
Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under development for Liver Cancer (Oncology).
Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of leading companies.
Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding Liver Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Topics Covered in the Report
- Global Liver Cancer Market Research,
- Global Liver Cancer Market Trends,
- Global Liver Cancer Market Share,
- Global Liver Cancer Market Growth,
- Global Liver Cancer Market Future,
- Liver Cancer Therapeutics Market analysis,
- Liver Cancer Therapeutics Market Developments,
- Liver Cancer Therapeutics Market Companies Revenue,
- Global Liver Cancer Market Outlook,
- Global Liver Cancer Industry Size,
- Global Liver Cancer Market Analysis,
- Global Liver Cancer Market Forecast,
- Global Liver Cancer Future Projections,
- Liver Cancer pipeline landscape,
- Liver Cancer Therapeutics Market,
- Global Liver Cancer Drugs Market,
- Liver Cancer Market,
- Liver Cancer Pipeline Market
For More Coverage Click On The Link Below:
https://www.kenresearch.com/healthcare/pharmaceuticals/liver-cancer-pipeline/78629-91.html
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-9015378249
